The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...